Phil Inter Pharma


Concise Prescribing Info
Calcitriol (vit D)
Treatment & prevention of vit D deficiency states & hypocalcemia in disorders eg, hypoparathyroidism & secondary hyperparathyroidism associated w/ chronic renal failure. Established postmenopausal osteoporosis.
Dosage/Direction for Use
Adult Initially 0.25 mcg daily or on alternate days, may be increased in steps of 0.25 mcg at 2-4 wk intervals to a usual dose of 0.5-1 mcg daily. Moderate to severe secondary hyperparathyroidism in dialysis patient Initially 0.5-4 mcg 3 times a wk, may be increased in steps of 0.25-1 mcg at 2-4 wk intervals. Max: 8 mcg 3 times a wk. Established postmenopausal osteoporosis 0.25 mcg bid.
May be taken with or without food:  May be taken w/ meals to reduce GI discomfort.
Hypersensitivity. All kinds of diseases related to hypercalcemia. Evidence of vit D toxicity.
Special Precautions
Patients w/ hypercalcemia; renal impairment/calculi or heart disease. Control plasma phosphate conc during therapy. Monitor plasma Ca conc at regular intervals, especially initially or if the symptoms suggest toxicity. Pregnancy & lactation. Infants (<3 yr & being taken hemodialysis & those breastfed by mothers receiving pharmacological doses of vit D).
Adverse Reactions
Hypersensitivity reactions. Excessive intake led to hyperphosphatemia or hypercalcemia.
Drug Interactions
Increased risk of hypercalcemia w/ thiazide diuretics, Ca or phosphate. Increased requirements w/ some antiepileptics (eg, carbamazepine, phenobarb, phenytoin & primidone). Reduced effectiveness w/ rifampicin & INH. Effect may be counteracted w/ corticosteroids. Inhibited metabolism of paricalcitol w/ ketoconazole & other potent CYP3A4 inhibitors.
ATC Classification
A11CC04 - calcitriol ; Belongs to the class of vitamin D and analogues. Used as dietary supplements.
Renatrol softgel cap 0.25 mcg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in